Oncology Venture’s website now in Chinese


Hoersholm, Denmark, 24th November 2017 – Oncology Venture Sweden AB (OV:ST) has as a courtesy to its Chinese stakeholders launched a Chinese  version in mandarin on selected sub-pages at its website www.oncologyventure.com

We heartily welcome our new readers!

For further information, please contact:

   Ulla Hald Buhl , COO and    Chief IR & Communications   Mobile: +45 2170 1049   [email protected] or Peter Buhl Jensen , CEOMobile: +45 21 60 89 22E-mail: [email protected]

About Oncology Venture Sweden AB  

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has an exclusive license to use the Drug Response Predictor (DRP™) technology in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors’ genes are screened first with DRP™ and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.

The current product portfolio: LiPlaCis ® for breast cancer in collaboration with Cadila Pharmaceuticals; Irofulven developed from a fungus for prostate cancer; and APO010 – an immuno-oncology product for multiple myeloma.

Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US-based company focusing on precision medicine for women’s cancers with a pipeline of three promising Phase 2 product candidates, and Danish OV-SPV 2 which will test and potentially develop the Novartis small molecule kinase inhibitor. Oncology Venture currently owns 92% of 2X Oncology Inc. and 40% of OV-SPV2 ApS.


Powered by WPeMatico